ProfileGDS5678 / 1460149_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 31% 31% 31% 36% 30% 33% 35% 30% 30% 31% 30% 31% 33% 31% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.743931
GSM967853U87-EV human glioblastoma xenograft - Control 22.7112631
GSM967854U87-EV human glioblastoma xenograft - Control 32.7148231
GSM967855U87-EV human glioblastoma xenograft - Control 42.7715736
GSM967856U87-EV human glioblastoma xenograft - Control 52.638830
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.8279833
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.8435135
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6802430
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6632830
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.687431
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6758630
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.664731
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.760433
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7031731